How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance (Q81279335)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

T Zenz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

S Häbe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

T Denzel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

D Winkler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

H Döhner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

S Stilgenbauer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

15 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

2257-2258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18480836%20AND%20SRC:MED&resulttype=core&format=json

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.114

7 January 2021

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.114

7 January 2021

Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.114

7 January 2021

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.114

7 January 2021

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.114

7 January 2021

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.114

7 January 2021